PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

Press Release
Written By Jamison Wright

https://news.puretechhealth.com/news-releases/news-release-details/puretech-reports-positive-topline-data-phase-1b-trial-lyt-200

Jamison Wright https://jamisonwright.com
Previous

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. FDA and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Next

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome